Novo Nordisk与Vivtex公司在2.1B交易上合作,利用先进的交付技术开发口服糖尿病和肥胖症药物。 Novo Nordisk partners with Vivtex on $2.1B deal to develop oral diabetes and obesity drugs using advanced delivery tech.

丹麦药商诺沃·诺迪斯克与美国生物技术Vivtex公司合作,一项价值21亿美元的交易,以开发供肥胖和糖尿病使用的口服生物药物。 Danish drugmaker Novo Nordisk has partnered with U.S. biotech Vivtex in a deal potentially worth $2.1 billion to develop oral versions of biologic drugs for obesity and diabetes. 合作利用Vivtex的先进药物运送技术,包括人工智能和肠道筛选系统,来改进消化道吸收像硫化物这样的大型分子的程度。 The collaboration leverages Vivtex’s advanced drug-delivery technology, including AI and gut-screening systems, to improve how large molecules like semaglutide are absorbed in the digestive tract. 诺沃将领导全球发展和商业化,旨在克服注射治疗的局限性。 Novo will lead global development and commercialization, aiming to overcome the limitations of injectable treatments. 这种合作伙伴关系支持Novo的战略,在2025年FDA批准口服Wegovy和推出口服Ozempic后,扩大其口服GLP-1疗法. The partnership supports Novo’s strategy to expand its oral GLP-1 therapies, following the 2025 FDA approval of oral Wegovy and the launch of oral Ozempic. 财务条件包括先期付款、里程碑和使用费,但具体细节没有披露。 Financial terms include upfront payments, milestones, and royalties, though specifics were not disclosed.